Dimension Therapeutics — Investor Presentation (August 2016)
21 slides from Dimension Therapeutics's investor presentation, Aug 11, 2016
Slide 1: Dimension Therapeutics, Inc. August 2016
Exhibit 99.1 Dimension Quality August 2016 of Science. Therapeutics, Quality Inc. of Life.
Slide 2: Forward-Looking Statements
Forward These “estimate,” timing, likelihood success our that quarter Dimension update The Company’s 2© 2016 management we information slides or ended progress expected. of Dimension Looking revise of strategic Therapeutics’ “project,” common and regulatory June any and contained the that, These Sta
Slide 3: Dimension Therapeutics: A leader in gene therapy for rare liver diseases
Dimension A discovering developing therapeutics people devastating diseases associated the unmet 3© leader 2016 liver medical living Dimension inrare Broad with Therapeutics new rare & for Robust with diseases need Manufactured product Unique Highly Deep Therapeutics scientific expertise pipeline ex
Slide 4: Enhanced Clade AAV Capsids and Industrialized Manufacturing Platform
Enhanced Clade AAV ~25% Proprietary Industrialized Downstream Manufacturing Source: Approach 4© 2016 Capsids EofDimension Gao AAV-Based Family the liver population et process • Mammalian al. affinity; •ofWell-established Scalable 2004 Therapeutics •Gene consistent Durable Jmay 16-110x Virol; Therapy
Slide 5: Robust Capsid and Intellectual Property Position
Robust Capsid Exclusive, AAV in Exclusive 2013 1Hemophilia GSDIa *License any 5© Transgene includes +application license 2016 upOTC 1 License vector to additional Intellectual AAV Dimension 8Deficiency Option excludes agreement specified Disease worldwide patent A* B* technology Capsid Intellectual
Slide 6: The Liver Is a Subset of Rare Monogenic Diseases Well-Suited to Gene Therapy
The >400 Subset Hemophilia Storage Source: Well-understood Well-described Restoration clinically Potential © Liver 2016 Described Believe Disorders Fagiuoli is Dimension orphan meaningful a Central to Urea Well-Suited Rare 5-10% biomarkers et drug disease Cycle Highly al. Monogenic Therapeutics6 Org
Slide 7: Broad Product Pipeline Addressing Diseases with Significant Medical Need
Broad © 2016Product Dimension Pipeline Therapeutics Addressing 7 Diseases with Significant Medical Need
Slide 8: Advancing Pipeline: Major Development Milestones Next 18 Months
Pipeline Hem File Value GSDIa OTC Expanded © Advancing Wilson 201612-18 candidates 2016 OTC B EUUS available Dimension •Set orphan Initiate IND•Hem Disease IMD orphan to7Months Deliver Program portfolio designation OTC data*•OTC development designation•GSDIa Therapeutics B ph additional Major Portfo
Slide 9: Inherited Metabolic Disease Programs
Inherited © 2016 Dimension MetabolicTherapeutics Disease Programs 9
Slide 10: Ornithine Transcarbamylase (OTC) Deficiency
Ornithine Disease X-linked, Genetic Adverse detoxification effects, Treatments Sources: carolguze.com/text/442-11-clinical_genetics.shtml; © 10 •Late 2016 coma, Dimension defect onset cognitive National urea Transcarbamylase Patient limited, in death cycle inmales ammonia~80% Population Urea &Therap
Slide 11: DTX301: Well-Understood Disease, Path to hPOC
DTX301: Well highly Durable phosphate •to ammonia; Source: © 11Serum Excess Increased designation 2016 orotic understood predictive Dimension ammonia Expression acid carbamoyl Replace neurotoxic converted serum (US/EU) • disease Adult preclinical OTC Therapeutics females of• Functional males hPOC to
Slide 12: Glycogen Storage Disease Type Ia (GSDIa)
Glycogen Disease Autosomal glucose Deficient Reduced (G6Pase) Strict uncooked Sources: © Research 12 2016diet Dimension metabolism Weinstein QOL, glucose-6-phosphatase Patient Storage starch and recessive, frequent long orPopulation Disease Glycosade® Therapeutics etterm inborn al. Dx feedings Hum r
Slide 13: DTX401: Well-Understood Disease, Path to hPOC
DTX401: Well highly Improved •liver glucose, Sources: hypoglycemia © Research Single Corresponding Glycogen Inability hypoglycemia 2016 understood predictive females Dimension dose raises Weinstein Replace G6Pase tobuild release AAV8 risk reduction disease up preclinical Activity G6Pase of Therapeut
Slide 14: Broad Inherited Metabolic Disease Product Opportunity
Broad Wilson Disease PKU Autosomal Citrullinemia Deficiency Type Sources: Neuro Vockley 2008; © Well highly type synthetase 20161Schilsky Inherited 2014; ATPase understood •Dimension Gen Barends predictive •Phenylalanine •WW •Autosomal in recessive Deficiency Ruegger Med phenylalanine argininosuccin
Slide 15: Hemophilia Programs
Hemophilia © 2016 Dimension Programs Therapeutics 15
Slide 16: Hemophilia: ~$6.2B Market
~$6.2B Disease Deficiency factor Joint severe bleeds Frequent, infusions Sources: shake/2014-04-02; www.ptcommunity.com/news/2014-12-29-000000/hemophilia-market-likely-undergo-major-changes; et © al. per 2016NEJM hemorrhages, patient IX disabilities; WW Dimension moderate Riley (FIX) of invasive, Pa
Slide 17: DTX101: Hemophilia B
DTX101 •Dosing: prophylactic Cohort ©Vector TPP* Gene Liver HEK293 Reduce severe 2016cassette specific 1targeting Dimension 1.6e12-1e13 capsid dosing Hem for dependency process Phase Hemophilia FIX BClade wild enhancer-promoter complete stable (?2% therapies I/II for Therapeutics type GC/kg, E for S
Slide 18: DTX201: Hemophilia A, Global Collaboration with Bayer
DTX201: Hemophilia A •company ©$20M High R&D DMTX Bayer leading commercialization 2016single-digit expense to upfront, Dimension responsible Global gene fund drug A therapy subsequent reimbursement up development Collaboration to Therapeutics tofor low $232M preclinical double-digit Global trials in
Slide 19: DTX201: Sustained hFVIII Expression in NHPs
DTX201: DTX201 3hFVIII Sustained Reduced Sources: ©of administered 60 than 2016 5weeks animals 16 Expression Dimension DMTX-PENN incidence for Durable FVIII RNA weeks; Hem retain IV expression expression 2A FVIII with in of Therapeutics ofexpression Non anti-FVIII 7IND-enabling 1.2e13 beyond data Ex
Slide 20: Dimension: Advancing Focus on Gene Therapy Milestones
Dimension: Advancing Focus milestones Building Highly Well-Capitalized © 2016on Experienced Dimension Gene Inherited Product A Leader Therapy Metabolic Expected Therapeutics Portfolio Team in Product Liver Strong cash Diseases Directed Broad Platform 20 runway R&D 7 Gene program Addressing and throu
Slide 21: Dimension Therapeutics, Inc.
Dimension Quality August 2016 of Science. Therapeutics, Quality Inc. of Life.
Dimension Therapeutics — Investor Presentation (August 2016) on 6ix